ME02604B - Her2 dnk vakcina kao dodatni tretman za kancere kod domaćih zivotinja - Google Patents
Her2 dnk vakcina kao dodatni tretman za kancere kod domaćih zivotinjaInfo
- Publication number
- ME02604B ME02604B MEP-2017-31A MEP3117A ME02604B ME 02604 B ME02604 B ME 02604B ME P3117 A MEP3117 A ME P3117A ME 02604 B ME02604 B ME 02604B
- Authority
- ME
- Montenegro
- Prior art keywords
- her2
- xenogeneic
- neu
- tumor
- antigen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 33
- 201000011510 cancer Diseases 0.000 title claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 40
- 239000000427 antigen Substances 0.000 claims 39
- 102000036639 antigens Human genes 0.000 claims 39
- 108091007433 antigens Proteins 0.000 claims 39
- 210000005075 mammary gland Anatomy 0.000 claims 24
- 241000282465 Canis Species 0.000 claims 17
- 201000009030 Carcinoma Diseases 0.000 claims 13
- 241000282472 Canis lupus familiaris Species 0.000 claims 9
- 239000013598 vector Substances 0.000 claims 9
- 238000002649 immunization Methods 0.000 claims 6
- 230000003053 immunization Effects 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 230000004069 differentiation Effects 0.000 claims 5
- 239000013612 plasmid Substances 0.000 claims 5
- 238000001356 surgical procedure Methods 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000004520 electroporation Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Claims (11)
1.Ksenogenski Her2/neu antigen koji je ksenogenski za Her2/neu antigen eksprimiran od strane ćelija mlečne žlezde psa za upotrebu u lečenju karcinoma/tumora mlečne žlezde psa kod psa koji pati od karcinoma/tumora mlečne žlezde psa pri čemu, ksenogenski Her2/neu antigen je u imunološki efikasnoj količini i ksenogenski Her2/neu antigen se primenjuje posle hirurškog uklanjanja tumora kod subjekata koji pate od navedenih kancera, i pri čemu ksenogenski Her2/neu antigen povezan sa tumorom mlečne žlezde je vektor koji sadrži DNK sekvencu koja kodira ksenogenski terapeutski Her2/neu antigen povezan sa tumorom mlečne žlezde pod kontrolom promotora koji stimuliše ekspresiju Her2/neu antigena povezanog sa tumorom mlečne žlezde kod psa.
2.Ksenogenski Her2/neu antigen prema patentnom zahtevu 1 za upotrebu prema patentnom zahtevu 1, naznačen time što ksenogenski diferencijacioni antigen povezan sa tumorom mlečne žlezde je Her2/neu pacova.
3.Ksenogenski Her2/neu antigen koji je ksenogenski za Her2/neu antigen eksprimiran od strane ćelija mlečne žlezde psa za upotrebu u lečenju tumora mlečne žlezde psa kod psa koji pati od karcinoma/tumora mlečne žlezde, pri čemu ksenogenski Her2/neu antigen povezan sa karcinomom/tumorom mlečne žlezde je vektor koji sadrži DNK sekvencu koja kodira ksenogenski terapeutski Her2/neu antigen povezan sa karcinomom/tumorom mlečne žlezde pod kontrolom promotora koji stimuliše ekspresiju ksenogenskog Her2/neu antigena povezanog sa tumorom mlečne žlezde kod psa, i pri čemu vektor ima sekvencu koja sadrži 106-3885 od sekvence kao što je navedena u SEQ ID NO:1 i ksenogenski Her2/neu antigen je primenjen posle hirurškog uklanjanja tumora kod subjekata koji pate od navedenih kancera.
4.Ksenogenski Her2/neu antigen prema patentnom zahetvu 1 ili 2 za upotrebu prema patentnom zahtevu 1 ili 2, pri čemu: 1) karcinom povezan sa Her2/neu je hirurški uklonjen; 2) primenjena je prva imunizacija koja sadrži prvi plazmid koji kodira ksenogenski Her2/neu antigen; i 3) buster imunizacija je primenjena preko elektrotransfera/elektroporacije; pri čemu je buster prvi plazmid ili drugi plazmid sposoban da eksprimira in vivo u psu različiti ksenogenski Her2/neu antigen, uključujući one kodirane od strane SEQ ID NO:3 ili 4, ili je rekobminantni vektor sposoban da eksprimira in vivo bilo koji Her2/neu protein, koji je sposoban da izazove terapeutski efikasan imuni odgovor protiv heterolognog Her2/neu eksprimiranog od strane karcinoma povezanog sa Her2/neu.
5.Ksenogenski Her2/neu antigen prema patentnom zahtevu 4 za upotrebu prema patentnom zahtevu 4, pri čemu: 1) prva imunizacija je primenjena bez igle; 2) prvi plazmid je sposoban da ekspimira in vivo u psu sekvencu kao što je navedena u SEQ ID NO:2; 3) buster imunizacija sadrži primenu plazmida iz koraka 2.
6.Ksenogenski Her2/neu antigen prema patentnom zahetvu 4 ili 5 za upotrebu prema patentnom zahtevu 4 ili 5, pri čemu je buster imunizacija data psima koji su preživeli jednom na svakih 3 do 6 meseci.
7. Ksenogenski Her2/neu antigen prema bilo kom od patentnog zahteva 1 ili 2 za upotrebu prema patentnom zahtevu 1 ili 2, pri čemu ksenogenski diferencijacioni antigen je primenjen pomoću DNK imunizacije subjekta sa DNK koja kodira ksenogenski diferencijacioni antigen u nevirusnom plazmidnom vektoru koji sadrži DNK koja kodira ksenogenski diferencijacioni antigen pod kontrolom promotora koji stimuliše ekspresiju ksenogenskog diferencijacionog antigena.
8. Ksenogenski Her2/neu antigen prema bilo kom od patentnih zahteva 1 ili 2 za upotrebu prema bilo kom od patentnih zahteva 1, 2 ili 7 izvedenu istovremeno sa resekcijom tumora mlečne žlezde (MGT).
9. Vektor koji je sposoban da eksprimira in vivo u psu protein kao što je naveden u SEQ ID NO:2 za upotrebu u lečenju karcinoma/tumora mlečne žlezde psa kod psa koji pati od karcinoma/tumora mlečne žlezde psa, pri čemu karcinom/tumor mlečne žlezde psa je karcinom/tumor mlečne žlezde povezan sa Her2/neu, pri čemu se vektor primenjuje posle hirurškog uklanjanja tumora kod subjekata koji pate od navedenih kancera.
10. Upotreba ksenogenskog Her2/neu antigena koji je ksenogenski za Her2/neu antigen eksprimiran od strane ćelija mlečne žlezde psa za proizvodnju leka za lečenje karcinoma/tumora mlečne žlezde psa kod psa koji pati od karcinoma/tumora mlečne žlezde psa, pri čemu ksenogenski Her2/neu antigen je u imunološki efikasnoj količini i ksenogenski Her2/neu antigen je primenjen posle hirurškog uklanjanja tumora kod subjekata koji pate od navedenih kancera, i pri čemu ksenogenski Her2/neu antigen povezan sa tumomorom mlečne žlezde je vektor koji sadrži DNK sekvencu koja kodira ksenogenski terapeutski Her2/neu antigen povezan sa tumorom mlečne žlezde pod kontrolom promotora koji stimuliše ekspresiju Her2/neu antigena povezanog sa tumorom mlečne žlezde kod psa.
11. Upotreba ksenogenskog Her2/neu antigena koji je ksenogenski za Her2/neu antigen eksprimiran od strane ćelija mlečne žlezde psa za proizvodnju leka za lečenje tumora mlečne žlezde psa kod psa koji pati od karcinoma/tumora mlečne žlezde psa, pri čemu ksenogenski Her2/neu antigen je vektor koji sadrži DNK sekvencu koja kodira ksenogenski terapeutski Her2/neu antigen povezan sa karcinomom/tumorom mlečne žlezde pod kontrolom promotora koji stimuliše ekspresiju ksenogenskog Her2/neu antigena povezanog sa tumorom mlečne žlezde kod psa, i pri čemu vektor ima sekvencu koja sadrži 106-3885 od sekvence kao što je navedena u SEQ ID NO:1 i ksenogenski Her2/neu antigen je primenjen posle hirurškog uklanjanja tumora kod subjekata koji pate od navedenih kancera.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39450510P | 2010-10-19 | 2010-10-19 | |
| EP11770986.5A EP2629791B1 (en) | 2010-10-19 | 2011-10-13 | Her2 dna vaccine as adjunct treatment for cancers in companion animals |
| PCT/US2011/056122 WO2012054294A1 (en) | 2010-10-19 | 2011-10-13 | Her2 dna vaccine as adjunct treatment for cancers in companion animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02604B true ME02604B (me) | 2017-06-20 |
Family
ID=44906393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-31A ME02604B (me) | 2010-10-19 | 2011-10-13 | Her2 dnk vakcina kao dodatni tretman za kancere kod domaćih zivotinja |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9040053B2 (me) |
| EP (1) | EP2629791B1 (me) |
| JP (2) | JP6113659B2 (me) |
| AU (1) | AU2011318369B2 (me) |
| CA (1) | CA2815125C (me) |
| CY (1) | CY1118707T1 (me) |
| DK (1) | DK2629791T3 (me) |
| ES (1) | ES2614880T3 (me) |
| HR (1) | HRP20170253T1 (me) |
| HU (1) | HUE030860T2 (me) |
| LT (1) | LT2629791T (me) |
| ME (1) | ME02604B (me) |
| MX (1) | MX343848B (me) |
| NZ (1) | NZ609198A (me) |
| PL (1) | PL2629791T3 (me) |
| PT (1) | PT2629791T (me) |
| RS (1) | RS55692B1 (me) |
| SI (1) | SI2629791T1 (me) |
| SM (2) | SMT201700061T1 (me) |
| WO (1) | WO2012054294A1 (me) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9040053B2 (en) * | 2010-10-19 | 2015-05-26 | Merial, Inc. | Her2 DNA vaccine as adjunct treatment for cancers in companion animals |
| US10434152B2 (en) * | 2014-02-20 | 2019-10-08 | Wayne State University | HER2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas |
| AU2015343369B2 (en) | 2014-11-03 | 2018-11-22 | Georgia Tech Research Corporation | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820180B2 (en) | 2004-09-24 | 2010-10-26 | The Trustees Of The University Of Pennsylvania | Listeria-based and LLO-based vaccines |
| US6328969B1 (en) | 1996-12-10 | 2001-12-11 | Sloan-Kettering Institute For Cancer Research | Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen |
| US7556805B2 (en) * | 1996-12-10 | 2009-07-07 | Sloan-Kettering Inststute for Cancer Research and The Animal Medical Center | Compositions for treatment of melanoma and method of using same |
| JP3993898B2 (ja) * | 1996-12-10 | 2007-10-17 | スローン−ケッタリング インスティチュート フォー キャンサー リサーチ | 改変された分化抗原によって刺激される分化抗原に対する免疫応答を刺激するための方法及び組成物 |
| JP4995575B2 (ja) * | 2003-11-12 | 2012-08-08 | アメリカ合衆国 | 乳癌を処置および予防するためのシステム |
| EP1687432A4 (en) * | 2003-11-13 | 2008-08-27 | Sloan Kettering Inst Cancer | COMPOSITIONS AND METHODS FOR SYNERGISTIC INDUCTION OF ANTITUMOR IMMUNITY |
| JP5985397B2 (ja) * | 2009-11-11 | 2016-09-06 | アドバクシス インコーポレイテッド | 組換えリステリア株およびそれを含む免疫原性組成物 |
| US9040053B2 (en) * | 2010-10-19 | 2015-05-26 | Merial, Inc. | Her2 DNA vaccine as adjunct treatment for cancers in companion animals |
-
2011
- 2011-10-13 US US13/272,651 patent/US9040053B2/en active Active
- 2011-10-13 SM SM20170061T patent/SMT201700061T1/it unknown
- 2011-10-13 SI SI201131121A patent/SI2629791T1/sl unknown
- 2011-10-13 EP EP11770986.5A patent/EP2629791B1/en active Active
- 2011-10-13 DK DK11770986.5T patent/DK2629791T3/en active
- 2011-10-13 CA CA2815125A patent/CA2815125C/en active Active
- 2011-10-13 HR HRP20170253TT patent/HRP20170253T1/hr unknown
- 2011-10-13 MX MX2013004222A patent/MX343848B/es active IP Right Grant
- 2011-10-13 NZ NZ609198A patent/NZ609198A/en unknown
- 2011-10-13 PT PT117709865T patent/PT2629791T/pt unknown
- 2011-10-13 ES ES11770986.5T patent/ES2614880T3/es active Active
- 2011-10-13 AU AU2011318369A patent/AU2011318369B2/en active Active
- 2011-10-13 ME MEP-2017-31A patent/ME02604B/me unknown
- 2011-10-13 HU HUE11770986A patent/HUE030860T2/en unknown
- 2011-10-13 WO PCT/US2011/056122 patent/WO2012054294A1/en not_active Ceased
- 2011-10-13 RS RS20170129A patent/RS55692B1/sr unknown
- 2011-10-13 JP JP2013534954A patent/JP6113659B2/ja active Active
- 2011-10-13 PL PL11770986T patent/PL2629791T3/pl unknown
- 2011-10-13 LT LTEP11770986.5T patent/LT2629791T/lt unknown
-
2015
- 2015-04-29 US US14/699,296 patent/US9901628B2/en active Active
-
2016
- 2016-09-01 JP JP2016170583A patent/JP6297641B2/ja active Active
-
2017
- 2017-01-26 SM SM201700061T patent/SMT201700061B/it unknown
- 2017-02-08 CY CY20171100185T patent/CY1118707T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1118707T1 (el) | 2017-07-12 |
| EP2629791B1 (en) | 2016-12-07 |
| WO2012054294A1 (en) | 2012-04-26 |
| JP6113659B2 (ja) | 2017-04-12 |
| US20150374808A1 (en) | 2015-12-31 |
| JP2016208988A (ja) | 2016-12-15 |
| HRP20170253T1 (hr) | 2017-04-07 |
| CA2815125C (en) | 2024-03-05 |
| MX343848B (es) | 2016-11-24 |
| PL2629791T3 (pl) | 2017-05-31 |
| MX2013004222A (es) | 2013-06-05 |
| RS55692B1 (sr) | 2017-07-31 |
| JP6297641B2 (ja) | 2018-03-20 |
| ES2614880T3 (es) | 2017-06-02 |
| EP2629791A1 (en) | 2013-08-28 |
| DK2629791T3 (en) | 2017-01-23 |
| SMT201700061T1 (it) | 2017-03-08 |
| AU2011318369A1 (en) | 2013-05-02 |
| CA2815125A1 (en) | 2012-04-26 |
| LT2629791T (lt) | 2017-02-27 |
| NZ609198A (en) | 2014-06-27 |
| HUE030860T2 (en) | 2017-06-28 |
| JP2013545447A (ja) | 2013-12-26 |
| US20120093841A1 (en) | 2012-04-19 |
| SMT201700061B (it) | 2017-03-08 |
| SI2629791T1 (sl) | 2017-05-31 |
| US9040053B2 (en) | 2015-05-26 |
| US9901628B2 (en) | 2018-02-27 |
| PT2629791T (pt) | 2017-03-03 |
| AU2011318369B2 (en) | 2014-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rice et al. | DNA vaccines: precision tools for activating effective immunity against cancer | |
| PH12020550600A1 (en) | Novel engineered t cell receptors and immune therapy using the same | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| Gong et al. | Advances of electroporation-related therapies and the synergy with immunotherapy in cancer treatment | |
| LT2163260T (lt) | Šimpanzės adenoviruso vakcinos nešikliai | |
| Chiarella et al. | Electroporation in DNA vaccination protocols against cancer | |
| Iezzi et al. | DNA vaccination against oncoantigens: a promise | |
| CA3018308A1 (en) | Treatment of cancer using recall antigens delivered by attenuated bacteria | |
| JP2012021028A5 (me) | ||
| ES2910709T3 (es) | Células T modificadas genéticamente resistentes a fármacos y procedimientos de utilización de las mismas | |
| Nemec et al. | Electroporation-based treatments in small animal veterinary oral and maxillofacial oncology | |
| Denies et al. | Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs | |
| ME02604B (me) | Her2 dnk vakcina kao dodatni tretman za kancere kod domaćih zivotinja | |
| Haller et al. | Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma | |
| CN102210875B (zh) | 一种可诱导免疫应答的具有lamp导向的bap31疫苗载体及其应用 | |
| Zare et al. | Introduction of a new recombinant vaccine based on GRP78 for breast cancer immunotherapy and evaluation in a mouse model | |
| ES2919134T3 (es) | Composición antitumoral | |
| Kim et al. | Immunogenicity and biodistribution of anthrax DNA vaccine delivered by intradermal electroporation | |
| Quaglino et al. | Chimeric DNA vaccines against ErbB2+ carcinomas: from mice to humans | |
| Oelkrug | Analysis of physical and biological delivery systems for DNA cancer vaccines and their translation to clinical development | |
| Pinzon-Charry et al. | Dendritic cell immunotherapy for breast cancer | |
| US20110104101A1 (en) | Immunotherapy for Unresectable Pancreatic Cancer | |
| Conforti et al. | Immunotherapy Applications (Telomerase and HER2) with Gene Electrotransfer | |
| CN101361983B (zh) | 一种肺癌dna质粒疫苗及其制备方法 | |
| SE535982C2 (sv) | Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi |